
Overview
Medical technology firm's preliminary Q4 revenue grew 2%
Company expects positive Adjusted EBITDA for full yr 2025
Outlook
Company to provide 2026 financial guidance during February earnings call
Result Drivers
ORDER TIMING SHIFT - Q4 revenue impacted by delay in large customer orders to 2026, per CEO Kevin Smith
B2B CHANNELS - Strong performance in business-to-business channels contributed to Q4 results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $82 mln | $88.60 mln (2 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Inogen Inc is $13.00, about 84.9% above its January 9 closing price of $7.03
Press Release: ID:nBw4jRZVda
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.